Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Lung Protective Immunity Elicited by Parental Yersinia-Vesicle Vaccine Against Pneumonic Plague

Award Number: R01AI201175
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/23/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

Lung Protective Immunity Elicited by Parental Yersinia-Vesicle Vaccine Against Pneumonic Plague - SUMMARY Yersinia pestis is a causative agent of plague. Among different plague forms, the primary pneumonic plague is the deadliest form of human disease.In addition, the appearanceof multiple drug-resistant Y. pestis may cause potential failure of antibiotic treatment. Thus, developing an effective plague vaccine for emergency use is imperative. Our of established studies have indicated that plague vaccine, Yersinia OMVs (O intramuscular (IM) immunization MV46-LcrV), instead of LcrV or F-V subunit antigen, induces robust with a new type adaptive responses in both systemic and lung mucosal compartments and significant elevation of alveolar macrophage (AM) numbers, which provide excellent short- and long-term protection against pulmonary Y. pestis challenge. However, how pneumonic propose infection. Moreover, a better understanding of lung immune mechanisms after immunization will undoubtedly IM O immunization distantly remodels lung immunity against plague, particularly about lung T cells, AMs, and their interrelation, remains elusive. Here, we to decipher these cells and their interrelation in the lung after immunization and upon pulmonary MV46-LcrV aid the development of effective pneumonic plague vaccines.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $633,136 )
2026	2026	ALBANY MEDICAL COLLEGE	47 NEW SCOTLAND AVE # A34	ALBANY	NY	12208	ALBANY	USA	Allergy and Infectious Diseases Research	000	1	7/23/2026	NEW	$633,136
														Subtotal = $633,136

Grand Total All Awards = $633,136

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Lung Protective Immunity Elicited by Parental Yersinia-Vesicle Vaccine Against Pneumonic Plague

Award Number: R01AI201175

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/23/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer